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Transcutaneous Gene Gun Delivery of hNC16A
Induces BPAG2-Specific Tolerance
Monika Ettinger1, Doris Peckl-Schmid1, Christina Gruber1, Martin Laimer1, Josef Thalhamer2,
Helmut Hintner1, Iris K. Gratz1,3,4 and Johann W. Bauer1,4
Immune recognition and rejection of tissues expressing transfected genes is a major complication of gene
replacement therapy for inherited genetic disorders. Owing to the high immunogenicity of human bullous
pemphigoid antigen 2 (hBPAG2), the induction and maintenance of tolerance to this neo-antigen is essential to
deliver the gene product to patients with epidermolysis bullosa junctionalis. In a skin grafting mouse model, we
used gene gun transfection with a construct encoding hNC16A, the immunodominant domain of hBPAG2, to
induce antigen-specific immune tolerance. Eighty percent of wild-type mice transfected with hNC16A showed
long-term survival of skin grafts expressing hBPAG2. Tolerance was stable and transferable by T cells but not by
B cells of tolerant mice to naive hosts. A dense Foxp3þ regulatory T-cell (Treg) infiltrate was noticed in grafts of
tolerant mice and depletion of these cells resulted in a loss of tolerance. Taken together, we show that long-
lasting hBPAG2-specific tolerance was induced with gene gun delivery of hNC16A through a Treg-dependent
mechanism. This is of relevance to patients undergoing gene therapy and has broader implications for the
treatment of antigen-specific autoimmune diseases.
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INTRODUCTION
Significant progress has been made in corrective gene
therapy of inherited skin diseases such as epidermolysis
bullosa (Laimer et al., 2006; Mavilio et al., 2006; Wally et al.,
2008; Murauer et al., 2011). However, in patients with null
mutations, there is a high risk of rejection of gene
therapy–treated tissue (Ghazizadeh et al., 2003). A particu-
larly high risk of autoimmune responses exists in junctional
epidermolysis bullosa where patients lack laminin-332 or
type XVII collagen and in dystrophic epidermolysis bullosa
with lacking type VII collagen, as these proteins are highly
immunogenic (Spirito et al., 2001; Sitaru et al., 2006; Hirose
et al., 2011). Using an animal model mimicking ex vivo gene
therapy, Olasz et al. (2007) have shown that neo-expression
of human bullous pemphigoid antigen 2 (hBPAG2) in the skin
led to unwanted immune responses and rejection of skin
grafts. Therefore, induction and maintenance of tolerance
toward this neo-antigen is critical to the success of gene
replacement therapy.
We used gene gun treatment to transfect cells in the
uppermost layers of the skin as an approach to introduce the
antigen and potentially induce tolerance toward an epider-
mal neo-self-antigen. Gene gun delivery enables direct
penetration of DNA-coated gold particles through the cell
membrane and subsequent expression of the antigen,
followed by proteosomal degradation and presentation of
antigenic peptides (Tang et al., 1992; Condon et al., 1996).
Mature dendritic cells have been shown to migrate to
draining lymph nodes (LNs) and are able to activate Ag-
specific CD4þ and CD8þ T cells, leading to productive
immune responses after this treatment (Stoecklinger et al.,
2007, 2011). Although the capacity of the gene gun to
immunize is well known, the mechanisms of gene gun
therapy to establish immune tolerance remain to be
elucidated. However, DNA vaccination has been shown to
have the potential to induce tolerance to self-antigens in
autoimmune settings such as experimental autoimmune
encephalomyelitis (Steinman, 2010b). Furthermore, delivery
of DNA has been used in clinical settings to prevent antibody
responses for treatment of multiple sclerosis (Steinman,
2010a) and recently for treatment of type 1 diabetes (Larsson
and Lernmark, 2011). Proposed mechanisms of antigen-
specific tolerance involve activation-induced cell death and
anergy, immune deviation, and generation or expansion of
regulatory T cells (Treg; Miller et al., 2007).
In this study, we utilize the before-mentioned mouse skin
grafting model mimicking ex vivo gene therapy to investigate
the potential of gene gun transfection for the induction of
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tolerance to the neo-self-antigen hNC16A and provide
mechanistic explanations how antigen-specific immune
tolerance can be established in gene replacement therapy
in the skin.
RESULTS
Gene gun transfection of hNC16A does not induce antibody
production in C57BL/6 mice
To investigate whether in vivo skin transfection elicits an
antibody response against secreted hNC16A, C57BL/6 mice
were transfected with hNC16A using the gene gun, and sera
were collected before transfection and weekly afterwards.
Both, with ELISA-specific for IgG against hNC16A and with
indirect immune fluorescence microscopy on human split
skin, no hNC16A-specific antibody could be detected at any
time point, after single or multiple transfections (Supplemen-
tary Figure S1 online) in C57BL/6 mice. All groups of mice
showed B-cell activation levels comparable to naive mice
(Supplementary Figure S2 online). To exclude that incorrect
antigen expression was the reason for absent antibody
responses in C57BL/6 mice, we tested the expression of
tissue plasminogen activator–hNC16A in in vitro transfection
studies followed by western blot analysis, which showed the
correct protein size of the expressed gene product (Supple-
mentary Figure S3 online). In addition, we showed that in
contrast to C57BL/6 mice, in vivo transfection of BALB/c skin
with NC16A resulted in specific IgG production (Supple-
mentary Figure S4 online) further proving that NC16A protein
expression and folding was correct.
Gene gun delivery of NC16A prevents graft rejection and
induces stable tolerance
Given that gene gun delivery of hNC16A in C57BL/6 mice
did not result in a productive humoral immune response, we
hypothesized that tolerance induction may have occurred. To
test the hypothesis, we used an approach with syngeneic
hBPAG2–expressing skin, grafted onto mice after gene gun
application of a construct encoding hNC16A. To test graft
survival in wild-type (WT) mice, full-thickness 1-cm2 grafts
from the tails of the transgenic (Tg) mice (heterozygous
hBPAG2 Tg) were placed onto the flanks of gender-matched,
syngeneic recipients. Eighty percent of hNC16A-transfected
mice retained hBPAG2 Tg skin grafts (n¼7/9) for 498 days,
whereas all non-transfected control WT animals as well as
animals treated with a similar-sized irrelevant antigen (a birch
pollen protein, Betv1a) rejected grafts within 28 days. The
stability of tolerance in hNC16A-pretreated mice was
assessed with a second graft, placed on mice that had
retained an initial Tg skin graft for 460 days (n¼ 2). Two of
two mice in this series accepted both, the initial and the
second skin grafts for the full observation period (4200
days), and both grafts showed normal histology without an
inflammatory infiltrate (Figure 1, Supplementary Figure S5
online). To exclude graft acceptance as the result of transgene
silencing in the skin graft, we verified transgene expression in
grafted skin by immunofluorescence (IF) staining, using an
antibody against hBPAG2 showing long-term expression
(Supplementary Figure S6 online).
Grafting induces anti-BM IgM, IgG1, and IgE, but only marginal
IgG2a
All mice grafted with gender-matched, syngeneic hBPAG2 Tg
skin developed hNC16A-specific IgG with high titer values
(1,000–10,000) within the first 20 days post first graft
placement, independent of the pretreatment (observation
period 98 days; Figure 2a). Similar kinetics were observed
using indirect IF microscopy, revealing that serum antibodies
bound human epidermal basement membrane (BM; Figure
2b). Titer values remained at these levels long term (98 days).
The hNC16A-treated group showed no increase in titer values
after placement of the second graft—the titer value remained
high over 202 days (titer 3,200, post first grafting). Anti-BM
IgG detected by IF analysis of human split skin corresponded
with hNC16A-specific IgG levels detected by ELISA. Further-
more, analysis of Ig subtypes revealed high IgG1, IgM, and
IgE (titer 4,000–30,000), but very low IgG2a (just above
background) over time (Supplementary Figure S7 online).
Complement-binding ability of the antibodies was examined
by conducting C3 fixation assays using the split skin protocol.
C3 staining was observed in rejected skin of non-transfected
mice, as well as in accepted grafts of hNC16A-treated mice
(Supplementary Figure S8 online).
Accepted grafts lack inflammation
To characterize the inflammatory response in accepted and
rejected skin grafts, skin sections were harvested at days 12,
18, 28, 64, and 202 post grafting, and tissue samples were
subjected to histological examinations. In the groups that
rejected the graft, an inflammatory infiltrate of predominant
lymphocytes was detected in the dermis 12 and 18 days after
grafting. At day 28, the sites of graft rejection showed
cutaneous ulceration, as well as fibrosis and a dense cell
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Figure 1. Graft survival after gene gun transfection with hNC16A. (a) Skin
of heterozygous hBPAG2-transgenic mice was grafted onto syngeneic wild-
type C57BL/6 recipients. Recipients were transfected with hNC16A before
grafting; the control group remained untreated or transfected with the
irrelevant antigen Betv1. Seven of nine hNC16A-treated mice accepted the
graft, whereas all the animals of the control groups rejected the graft
(observation period 98 days). A second graft, which was placed on the
opposite site on day 64 (*), showed survival as well (full observation period
202 days, n¼2). (b) Graft appearance of accepted and rejected skin graft.
hBPAG2, human bullous pemphigoid antigen 2.
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infiltrate in the dermis. Sixty-four days after grafting, grafted
skin was completely rejected and the wound was fully
healed. In contrast, biopsies of accepted grafts displayed only
a spotty parakeratotic epidermis with subtle superficial
dermal fibrosis in absence of an appreciable cellular
inflammatory infiltrate (Figure 3).
Only lymphocytes from mice with accepted grafts transfer
full graft tolerance
To elucidate whether lymphocytes have a role in the
maintenance of tolerance in hNC16A-transfected mice,
we injected WT mice with splenocytes or LN cells of mice
tolerating the grafts (n¼ 11) 1 day before grafting hBPAG2-
expressing skin. Transfer of splenocytes (n¼ 3/3) and LN
cells (n¼2/2) from mice that had accepted the graft after
gene gun transfection for 98 days resulted in long-term graft
acceptance. To determine whether gene gun transfection alone
is sufficient to induce tolerance or whether the subsequent
challenge was necessary to fully establish tolerance, we
adoptively transferred cells from mice only pretreated with
gene gun transfection (2 weeks before cell isolation) without
subsequent grafting. Interestingly, transfer of cells from only
gene gun–treated animals did not prevent from graft rejection
(Figure 4). We next asked whether the inflammatory response
induced by the skin grafting procedure alone would be
sufficient to fully establish tolerance or whether the process
was antigen specific. To that end, we grafted hNC16A-
transfected mice with WT skin, isolated CD4þCD25þ cells
(day 49), and adoptively transferred these to WT mice 1 day
before grafting. All grafts were rejected, indicating that antigen-
specific challenge was necessary to fully activate and/or
expand antigen-specific Treg in order to prevent graft rejection
(3/3; Figure 4, Supplementary Figure S9 online).
Regulatory T cells have a major role in graft tolerance
To test the role of immunoregulatory cells in our model of
gene gun–induced tolerance, immunohistological analysis of
the accepted skin grafts stained for Foxp3þ cells was carried
out. The skin sections of pretransfected animals showed a
deep dermal Treg infiltrate at the site of the graft on days 14
(not shown) and 18, decreasing on day 26. Naive mice
showed a Treg infiltrate on day 18, increasing on day 28 at the
time of rejection, and this infiltrate was situated primarily in
the upper dermis and in the area of rejected skin (Supple-
mentary Figure S10 online). To further examine the role of
Treg in induction and maintenance of graft tolerance, CD25
þ
cells were depleted before grafting (2 weeks after gene gun
and 2 weeks before grafting) using an anti-CD25 antibody.
All mice (n¼6/6) treated with anti-CD25 rejected the graft
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Figure 2. Antibody production against BM following hBPAG2-transgenic
graft placement, measured with hNC16A-specific IgG ELISA. (a) An anti-
basement membrane (BM) IgG on split skin (b). Anti-BM IgG developed in all
hNC16A-treated and grafted mice in a similar way as in naive grafted mice.
Antibody titer values increased at day 20 and showed a plateau over the
observation period, and did not significantly change after placement of the
second graft (n¼2). Transfection with hNC16A without grafting elicited no
hNC16A-specific IgG titer, as well as subsequent grafting with wild-type (WT)
skin. hBPAG2, human bullous pemphigoid antigen 2.
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Figure 3. Histological analysis of skin grafts. Skin graft biopsies from tolerant
gene gun–transfected mice and control mice. Upper panel: graft recipient
treated with hNC16A gene gun transfection before grafting; lower panel: graft
recipient untransfected control mouse. Left: 18 days after grafting, right: 26
days after grafting. Representative sections were taken and stained with
hematoxylin and eosin (original magnification  40).
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within the first 3 weeks, whereas three out of four mice treated
with isotype control accepted the graft (Figure 5a, Supple-
mentary Figure S11 online). Furthermore, we asked whether
Treg were not only required for the induction of tolerance but
also for its maintenance. For this purpose, Treg in tolerant WT
mice, bearing the graft for 42 days, were depleted using the
anti-CD25 antibody. Fifty percent of the mice (n¼ 2/4)
rejected the graft between days 14 and 20 after depletion
(Figure 5b, Supplementary Figure S12 online). Transfer of
CD4þCD25þ or CD4 cells from tolerant mice revealed that
only the transfer of CD4þCD25þ cells prevented graft
rejection, whereas transfer of CD4 cells did not (Figure 5c,
Supplementary Figure S13 online). To assess the role of B cells
in this model, we adoptively transferred B cells (CD19þ ) of
tolerant mice (bearing viable hBPAG2 Tg skin grafts for 76
days) into WT mice 1 day before grafting. B cells from naive
mice served as control. Five of five mice treated with CD19þ
cells from tolerant mice rejected the graft within week 7, as
well as those mice adoptively transferred with CD19þ cells
from naive mice (Supplementary Figure S14 online and
Supplementary Figure S15 online). In addition, to investigate
whether tolerance to hBPAG2 Tg skin could be passively
transferred by sera from tolerant mice, naive mice were
treated with serum from mice that had accepted their graft for
20–27 days. After serum transfer, four of four mice rejected the
graft, indicating that constituents of the serum are not
responsible for the immunosuppressive effect (Supplementary
Figure S16 online).
DISCUSSION
Immune responses toward a neo-antigen are a major
limitation of gene therapy. We have investigated the potential
of gene gun transfection to induce peripheral tolerance and
tested gene gun application in a skin grafting setting
comparable with ex vivo gene therapy. We have shown that
this approach can induce robust antigen-specific tolerance
and permit the acceptance of tissue expressing a neo-antigen.
In our model, system grafting of WT C57BL/6 mice with
hBPAG2 Tg skin led to graft rejection and production of
hNC16A-specific IgG, as previously shown by Olasz et al.
(2007). Prior gene gun transfection of hNC16A led to
acceptance of skin grafts expressing the antigen. Interestingly,
even though gene gun transfection by itself did not induce an
antibody response, it did not prevent antibody formation after
grafting. We observed a high level of IgG in tolerant
hNC16A-treated mice and analyzed the hNC16A-specific Ig
response in detail, revealing high serum levels of IgG1 and
IgM antibodies, whereas the level of IgG2a and IgG2c was
hardly detectable. However, this low level was apparently
sufficient to fix complement, as shown by C3 fixation studies.
This lack of correlation of antibody titer values with graft
injury was previously described (Zhang et al., 2009) using an
orthotopic murine skin transplantation method with green
fluorescent protein as a model antigen. Another group
working with type XVII collagen immunization has shown
that SJL/J mice immunized with murine BP180 protein
developed antigen-specific IgG, although no correlation with
disease severity was observed. Unfortunately, none of these
studies, including ours, has a satisfactory explanation for this
phenomenon.
To investigate the mechanism of tolerance induction, we
carried out immunohistological analysis of graft biopsies. We
concentrated on studies detecting Foxp3þ T cells, as Treg are
known to have a major role in tolerance induction and
maintenance (Sakaguchi et al., 2008; Wing and Sakaguchi,
2010). Furthermore, it has recently been shown that antigen-
specific Treg become activated and migrate to the site of
antigen expression (i.e., skin) where they reside as memory
Treg, which attenuate subsequent autoimmune reactions
when antigen is reexpressed (Rosenblum et al., 2011). In
line with those findings, we showed that a second graft
placed on tolerant mice more than 60 days after the first graft
was also accepted. Foxp3þ T cells were detected in the
antigen-expressing grafts of tolerant mice at days 12 and 18
after grafting. Cell transfer studies propose lymphocytes as
key mediators in mediating graft acceptance. In addition, the
transfer studies prove that regulatory cells are present in the
LNs and spleen up to 98 days after graft placement and are
able to initiate and/or maintain tolerance. Gene gun transfection
seemed to initiate a tolerogenic state, which was stabilized by
the antigen-specific challenge of skin grafting, as indicated by
the fact that transplantation tolerance could only be
transferred by lymphocytes from successfully grafted mice
but not from only gene gun–transfected mice. Furthermore,
only CD4þCD25þ cells from animals that had received a Tg
graft, but not CD4þCD25þ cells from mice that had received
grafts lacking the hBPAG2 antigen (i.e., inflammatory
stimulus without antigen), could transfer tolerance. This
indicates that gene gun transfection induced an antigen-
specific regulatory response, which was boosted and
expanded by the grafting procedure. The importance of Treg
for induction and maintenance of tolerance in our system
was also confirmed by in vivo depletion of CD25þ cells,
which completely abrogated graft acceptance when Treg were
depleted before grafting (induction phase), and led to graft
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Figure 4. Adoptive transfer of lymphocytes from tolerant mice. Splenocytes
(5107, Spl) or lymph node cells (1107, LN) from mice tolerating the
graft (day 98) were transferred to wild-type (WT) mice 1 day before grafting
hBPAG2-expressing skin. Cells from mice with long-term graft survival
prevented from graft rejection, transfection with gene gun alone did not
prevent graft rejection. Naive mice served as control. Furthermore, transfer of
CD4þCD25þ cells (day 49) from hNC16A-transfected mice, grafted with WT
skin, led to graft rejection (n¼ 3/3).
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rejection in 50% of mice by depletion at day 42 (main-
tenance phase). B cells had no crucial role in tolerance
induction as transfer of CD19þ cells from mice accepting the
graft led to graft rejection, as well as transfer of CD4 cells.
The fact that gene gun transfection offers the possibility to
trigger tolerance by inducing Treg subsets has already been
demonstrated by Lobell et al. (2003) and Goudy et al. (2008).
Furthermore, gene vaccination has also been demonstrated in
an immunosuppressive context in autoimmune diseases
(experimental autoimmune encephalomyelitis; Ruiz et al.,
1999). Moreover, clinical trials have been carried out using
various antigen-specific tolerance strategies, including DNA
vaccination in multiple autoimmune diseases, i.e., multiple
sclerosis, rheumatoid arthritis, and type 1 diabetes (Steinman,
2004). Hence, gene gun transfection can be used therapeu-
tically not only for immunization but also for the induction of
regulatory immune responses and tolerance.
In summary, we have demonstrated the prevention of neo-
antigen-mediated rejection of skin grafts by in vivo gene gun
transfection with hNC16A. We conclude that DNA gene gun
delivery of a neo-antigen can induce antigen-specific
tolerance to a skin graft. Methods derived from this work
may be useful clinically for ex vivo gene therapy.
MATERIALS AND METHODS
Mice
C57BL/6 hBPAG2 tg (Tg) mice, expressing hBPAG2 in the BM of the
skin (hBPAG2 Tg), were obtained by Kim Yancey, Southwestern
Medical School at Dallas, Texas. Female BALB/c and C57BL/6 mice
(8- to 10-week old) were purchased from Charles River Laboratories
(Sulzfeld, Germany). Mice were housed under sun protection factor
conditions in the animal facility at the University of Salzburg and at
the Paracelsus Medical University Salzburg, Austria, according to
the institutional and national guidelines for animal care and use. All
experiments described in this study were approved by the Austrian
Federal Ministry for Science and Research.
Design of construct
NC16A was amplified from complementary DNA of human
keratinocytes using primers specific for NC16A (Genebank acces-
sion number NM_000494, primer sequence fwd: 50-tagaggaggtgag-
gaagctgaagg-30, rev: 50-tcatcggagatttccattttcctgttccatc-30 inserting a
stop codon). We truncated NC16A (10 amino acids) at the 50 end to
delete the coiled-coil motif located on its N-terminus. The
complementary DNA of Betv1 was gratefully obtained from Richard
Weiss (University of Salzburg, Austria). Constructs were cloned into
pEF6/V5 His TOPO vector (Invitrogen, Karlsruhe, Germany),
including the endoplasmic reticulum-targeting sequence of human
tissue plasminogen activator (TPA leader) for secretion of the
contructs and 6 His-tag for detection. Constructs were purified
by use of the Qiagen Endofree kit (Qiagen, Hilden, Germany).
Epidermal transfection using gene gun
The skin of BALB/c and C57BL/6 mice was transfected in vivo with
the constructs via gene gun application. For this purpose, DNA-
coated gold particles were produced according to manufacturer’s
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Figure 5. Regulatory T cells are involved in graft acceptance. Depletion of CD25þ cells at early stage. (a) hNC16A-transfected wild-type (WT) mice were
depleted of CD25þ cells 2 weeks after gene gun application and 2 weeks before grafting. All depleted mice rejected the graft within week 4, whereas three of
four isotype-treated mice accepted the graft. Depletion of CD25þ cells at day 42. (b) WT mice were transfected with gene gun encoding hNC16A before
grafting, and CD25þ T cells were depleted at day 42. Two of four mice rejected the graft within weeks 5 and 6. Transfer of CD4þCD25þ cells. (c) One day
before grafting, WT mice received CD4þCD25þ cells and CD4 cells of mice that had accepted the graft for 98 days. Transfer of CD4þCD25þ cells inhibited
graft rejection, but not transfer of CD4 cells. hBPAG2, human bullous pemphigoid antigen 2; Tg, transgenic.
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instructions. Briefly, plasmid DNA was precipitated onto gold beads
(1.6 mm diameter, Bio-Rad, Munich, Germany) using CaCl2 in the
presence of spermidine (Sigma-Aldrich, Vienna, Austria). Mice
received two nonoverlapping shots onto the shaved abdominal skin.
With each shot, 1mg of DNA immobilized onto 0.5mg gold particles
was delivered at a pressure of 400 pounds per square inch (psi) with
a Helios gene gun (Bio-Rad).
Flow cytometric analysis
LN cells were isolated from mechanically disrupted LN tissue by
collagenase D (1mgml1 in Hank’s Balanced Salt Solution) and
DNase I (0,12mgml1 in Hank’s Balanced Salt Solution) digestion
(Roche; Vienna, Austria, 40minutes at 37 1C, with gentle agitation),
and were filtered through 70-mm nylon mesh filters. For surface
staining, cells were incubated with anti-CD4 mAb, anti-CD8 mAb,
anti-CD19 mAb, and anti-CD11c mAb (eBioscience, Vienna, Austria)
in combination with various activation markers (CD86, CD62L,
CD69, and CD25, all from eBioscience). Cells were recorded on a
Beckman Coulter flow cytometer (FC500; Vienna, Austria) and
analyzed by FlowJo (Tree Star, Ashland, OR).
Serum preparation and ELISA
Serum was prepared weekly by centrifugation of blood samples. For
detection of hNC16A-specific Igs, high-protein-binding ELISA plates
(Nunc MaxiSorp, eBioscience) were coated overnight at 4 1C with
1mgml1 recombinant hNC16A in phosphate-buffered saline. Plates
were blocked (phosphate-buffered saline containing 0.1% Tween
and 0.5% BSA) for 1 hour at room temperature. Serial dilutions of
mouse sera were incubated for 1 hour at room temperature. Plates
were washed and Ag-specific Ig were detected with isotype-specific
horseradish peroxidase-conjugated detection antibodies (IgG-,
IgG2a-, IgM-, IgE-horseradish peroxidase, respectively, Serotec,
Du¨sseldorf, Germany). Antibody titer values were determined by
end-point titration and expressed as the dilution factor, yielding a
signal three times higher than the detection limit.
Indirect IF microscopy
Sera from mice grafted with hBPAG2 Tg skin were diluted 1:300 and
tested for anti-BM IgG by indirect IF microscopy of 1M NaCl split
human skin. IF stainings were examined by one independent
observer and scored as follows: negative (), weak (þ ), moderate
(þ þ ), strong (þ þ þ ), and very strong (þ þ þ þ ). This scoring
was based on the intensity of BM staining according to routine IF
microscopy in bullous autoimmune diseases. The score þ þ þ þ
corresponds to a titer value of 1:10,000 in ELISA.
Skin grafting
Tail skin was taken from hBPAG2 Tg mice and grafted onto the backs
of gender-matched WT C57BL/6 recipients (Rosenberg and Singer,
1988). Bandages were removed at day 7, and grafts were checked
twice a week until day 30, then weekly, for viability and size. Skin grafts
were graded as lost if their area became 70% or less of their original size.
Histological analysis of skin grafts
Biopsies of 4mm were obtained at various time points after grafting.
Samples were placed into Michel’s medium, embedded in paraffin,
sectioned at 5-mm thickness, and stained with hematoxylin and eosin.
For immunohistochemistry, sections were deparaffinized using xylene
and graded alcohols, followed by a heat-induced antigen retrieval in
EDTA buffer, pH 9.0, at 98 1C for 40minutes. Validated polymer-based
(Envision, Dako DN, Vienna, Austria) immunohistochemistry was per-
formed in combination with a peroxidase substrate–chromogen system.
For Treg staining, the following primary antibody was used: rabbit poly-
clonal anti-Foxp3 antibody (ab54501, 1:50; Abcam, Cambridge, UK).
Adoptive transfer studies
A total of 5 107 splenocytes and 1 107 cells from LN of NC16A-
treated WT mice, bearing intact and viable hBPAG2 Tg skin grafts for
98 days, were adoptively transferred to WT mice 1 day before grafting.
In a separate set of experiments, lymphocytes from mice transfected
with the constructs encoding hNC16A were transferred (2 weeks after
gene gun); lymphocytes from naive mice served as control.
Furthermore, CD4þCD25þ T cells were isolated from splenocytes
and LN cells from mice bearing intact and viable hBPAG2 Tg skin
grafts for 64 days, using EasySep isolation kit (StemCell Technologies,
Grenoble, France). CD4þCD25þ (3 105 per mouse) and CD4
(5 107 per mouse) cells were injected into WT mice 1 day before
grafting. In addition, hNC16A-transfected mice were grafted with WT
skin, CD4þCD25þ were isolated 49 days after grafting, and
adoptively transferred (3 105 per mouse) to WT mice 1 day before
grafting. Purity was determined by FACS analysis using anti-CD4 and
anti-CD5mAb (eBioscience). Graft viability was observed weekly.
CD25þ T-cell depletion studies
To examine whether Treg depletion abolishes the maintenance of
tolerance, gene gun–transfected and grafted mice were injected
intravenously with 50 mg anti-mouse CD25 antibody (Clone PC61.5,
eBioscience) at day 42. To elucidate whether the gene gun
transfection induces or activates Tregs, we additionally depleted Tregs
during the early stage of the experiment (2 weeks after gene gun and
2 weeks before grafting to avoid depletion of effector cells). Mice
were injected intraperitoneally with 500mg anti-mouse CD25
antibody (Clone PC61.5, eBioscience) and rat IgG1 isotype (Clone:
eBRG1, eBioscience) as control, respectively.
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